New Drug Extends Pancreatic Cancer Survival

Daraxonrasib Doubles Pancreatic Cancer Survival in Clinical Trial

A clinical trial presented at the American Society of Clinical Oncology's (ASCO) annual meeting in Chicago demonstrated that the daily oral medication daraxonrasib doubled the median survival time for patients with advanced pancreatic cancer. The study, involving 500 patients with metastatic pancreatic cancer, found that those receiving daraxonrasib lived for an average of 13.2 months, compared to 6.6 to 6.7 months for patients undergoing chemotherapy. This represents a significant improvement in patient outcomes for a cancer with historically limited treatment options.

The drug, daraxonrasib, functions by targeting the Kras protein, which is a key driver in over 90% of pancreatic ductal adenocarcinoma (mPDAC) cases. It operates as a Ras(On) multi-selective inhibitor, effectively deactivating the Kras protein to impede cancer growth, irrespective of specific Kras variants. This mechanism of action offers a broad therapeutic approach against a prevalent oncogenic pathway in pancreatic cancer.

Beyond extending survival, the trial also indicated that daraxonrasib exhibited fewer side effects compared to traditional chemotherapy regimens. This improved tolerability could enhance the quality of life for patients undergoing treatment. The findings suggest a potential shift in the treatment landscape for advanced pancreatic cancer, offering a new therapeutic avenue with both efficacy and a more favorable side-effect profile.